1. Neoadjuvant therapy and major arterial resection for potentially reconstructable arterial involvement by stage 3 adenocarcinoma of the pancreas.
- Author
-
Loveday BPT, Zilbert N, Serrano PE, Tomiyama K, Tremblay A, Fox AM, Segedi M, O'Malley M, Borgida A, Bianco T, Creighton S, Dodd A, Fraser A, Moore M, Kim J, Cleary S, Moulton CA, Greig P, Wei AC, Gallinger S, Dhani N, and McGilvray ID
- Subjects
- Adolescent, Adult, Aged, Biopsy, Carcinoma, Pancreatic Ductal blood supply, Carcinoma, Pancreatic Ductal diagnosis, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy methods, Pancreatic Neoplasms blood supply, Pancreatic Neoplasms diagnosis, Plastic Surgery Procedures methods, Retrospective Studies, Tomography, X-Ray Computed, Young Adult, Carcinoma, Pancreatic Ductal therapy, Hepatic Artery surgery, Mesenteric Artery, Superior surgery, Neoplasm Staging, Pancreatectomy methods, Pancreatic Neoplasms therapy, Vascular Surgical Procedures methods
- Abstract
Background: Stage 3 pancreatic ductal adenocarcinoma (PDAC) is defined by arterial involvement. This study objective was to evaluate outcomes for patients with stage 3 PDAC with potentially reconstructable arterial involvement, considered for neoadjuvant therapy (NAT) and pancreatic resection, and to compare outcomes following arterial (AR) and non-arterial resection (NAR)., Methods: This study included patients from 2009 to 2016 with biopsy-proven stage 3 PDAC who were offered NAT before surgical exploration. AR was performed if required to achieve R0 resection. Time to event outcomes were analysed from diagnosis date., Results: 87/89 patients (97.8%) received NAT (chemotherapy 41.6%, chemotherapy/radiotherapy 56.2%). 46/89 (51.7%) underwent exploration; 31 underwent resection (AR n = 20, NAR n = 11). AR patients had longer operative time (681 vs. 563 min, p = 0.006) and more blood loss (1600 vs. 575 mL, p = 0.0004), with no difference for blood transfusion, pancreatic fistula, length of stay, reoperation, or mortality. R0 rate was 30/31. Post-resection 90-day mortality was 3.2%. Median overall survival was statistically comparable between the AR and NAR groups (19.7 vs. 28.4 months, p = 0.41)., Conclusions: AR had comparable clinical and oncologic outcomes to NAR. Following careful selection and non-progression after NAT, major AR may cautiously be considered if required to obtain a negative resection margin., (Copyright © 2018. Published by Elsevier Ltd.)
- Published
- 2019
- Full Text
- View/download PDF